文献速递肝病消化道肿瘤与早癌

为推荐接受TACE的肝细胞癌患者开发预后评分:一项多中心观察性研究

Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study.
PubMed 文献 · J Hepatol · 2019-01-18

基于24个中心1604例接受TACE的不可切除肝细胞癌患者(Child-Pugh A5-B7、体能状态0),随机分为训练组807例和验证组797例,开发并验证了「六和十二」评分(最大肿瘤直径cm+肿瘤数目),以6和12为界将患者分为3层,中位生存期分别为49.1、32.0和15.8个月。

要点

  • 「六和十二」评分=最大肿瘤直径(cm)+肿瘤数目,在训练集和验证集中均优于其他现有模型。
  • 评分≤6、>6但≤12、>12三组中位生存期分别为49.1、32.0和15.8个月。
  • 该评分可用于推荐TACE的BCLC A/B期患者风险分层和生存预测,尚需外部验证。

核心结论

  • 「六和十二」评分可能成为对推荐TACE的BCLC A/B期肝细胞癌患者进行分层和个体生存预测的简便工具,表现和区分度良好,尚需进一步外部验证。

研究设计与样本

  • 多中心观察性研究,纳入2010年1月至2016年5月来自24个三级中心的1604例初治不可切除肝细胞癌患者,Child-Pugh A5-B7、体能状态0,均接受TACE。
  • 患者随机分为训练组807例和验证组797例,开发并验证预后模型。

主要发现

  • 最终模型为线性预测值=最大肿瘤直径(cm)+肿瘤数目,在训练集和验证集及不同亚组中均持续优于其他现有模型。
  • 评分≤6组中位生存期49.1个月(95%CI 43.7-59.4),>6但≤12组32.0个月(95%CI 29.9-37.5),>12组15.8个月(95%CI 14.1-17.7),三组差异显著。

临床怎么用

  • 作者认为「六和十二」评分可用于临床实践中对推荐TACE的患者进行分层,并有助于设计采用可比标准的临床试验。
  • 作者指出该评分尚需进一步外部验证。

局限性

  • 原文指出需要进一步外部验证该评分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Previous prognostic scores for transarterial chemoembolization (TACE) were mainly derived from real-world settings, which are beyond guideline recommendations. A robust model for outcome prediction and risk stratification of recommended TACE candidates is lacking. We aimed to develop an easy-to-use tool specifically for these patients. METHODS: Between January 2010 and May 2016, 1,604 treatment-naïve patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh A5-B7 and performance status 0 undergoing TACE were included from 24 tertiary centres. Patients were randomly divided into training (n = 807) and validation (n = 797) cohorts. A prognostic model was developed and subsequently validated. Predictive performance and discrimination were further evaluated and compared with other prognostic models. RESULTS: The final presentation of the model was "linear predictor = largest tumour diameter (cm) + tumour number", which consistently outperformed other currently available models in both training and validation datasets as well as in different subgroups. The thirtieth percentile and the third quartile of the linear predictor, namely 6 and 12, were further selected as cut-off values, leading to the "six-and-twelve" score which could divide patients into 3 strata with the sum of tumour size and number ≤6, >6 but ≤12, and >12 presenting significantly different median survival of 49.1 (95% CI 43.7-59.4) months, 32.0 (95% CI 29.9-37.5) months, and 15.8 (95% CI 14.1-17.7) months, respectively. CONCLUSIONS: The six-and-twelve score may prove an easy-to-use tool to stratify recommended TACE candidates (Barcelona Clinic Liver Cancer stage-A/B) and predict individual survival with favourable performance and discrimination. Moreover, the score could stratify these patients in clinical practice as well as help design clinical trials with comparable criteria involving these patients. Further external validation of the score is required. LAY SUMMARY: There is currently no prognostic model specifically developed for recommended or ideal transarterial chemoembolization (TACE) candidates with hepatocellular carcinoma, despite these patients being frequently identified as the best target population in pivotal randomized controlled trials. The six-and-twelve score provides patient survival prediction, especially in ideal candidates of TACE, outperforming other currently available models in both training and validation sets, as well as different subgroups. With cut-off values of 6 and 12, the score can stratify ideal TACE candidates into 3 strata with significantly different outcomes and may shed light on risk stratification of these patients in clinical practice as well as in clinical trials.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Wang Q, Xia D, Bai W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019. PMID: 30660709. doi:10.1016/j.jhep.2019.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。